AKRO · Categories · Form 4
AKRO - SEC Form 4 insider transactions
Akero Therapeutics Inc. (AKRO) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.
Recent Form 4 for AKRO
- Director Heyman Tomas J. returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Director Xu Yuan returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- President and CEO Cheng Andrew returned 436,837 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Director Harrison Seth Loring returned 293,762 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Director Graham G. Walmsley returned 1,302,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Director Judy Chou returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Scientific Officer Rolph Timothy returned 282,149 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Director Iwicki Mark T returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Technology Officer Gangloff Scott A. returned 26,351 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Financial Officer White William Richard returned 57,752 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Development Officer Yale Catriona returned 74,800 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Director Henderson Jane returned 9,398 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Officer Lamy Patrick returned 29,891 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Operating Officer Young Jonathan returned 260,189 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Scientific Officer Rolph Timothy exercised 152,678 shares at a strike of $4.09, increasing direct ownership by 118% to 282,149 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Operating Officer Young Jonathan gifted 9,259 shares and exercised 12,550 shares at a strike of $23.13, increasing direct ownership by 2% to 200,189 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- President and CEO Cheng Andrew gifted 74,538 shares, decreasing direct ownership by 15% to 436,837 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Scientific Officer Rolph Timothy gifted 37,100 shares, decreasing direct ownership by 22% to 129,471 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- President and CEO Cheng Andrew gifted 14,739 shares, decreasing direct ownership by 3% to 511,375 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Development Officer Yale Catriona exercised 8,266 shares at a strike of $24.19, increasing direct ownership by 12% to 74,800 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- President and CEO Cheng Andrew exercised 30,000 shares at a strike of $19.87 and sold $1,619,340 worth of shares (30,000 units at $53.98) (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Director Graham G. Walmsley exercised 90,832 shares at a strike of $20.55, increasing direct ownership by 4,190% to 93,000 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Scientific Officer Rolph Timothy exercised 12,500 shares at a strike of $28.35 and sold $576,001 worth of shares (12,500 units at $46.08) (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- President and CEO Cheng Andrew exercised 52,212 shares at a strike of $0.61, increasing direct ownership by 11% to 526,114 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Operating Officer Young Jonathan exercised 12,500 shares at a strike of $21.10 and sold $596,978 worth of shares (12,500 units at $47.76) (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Operating Officer Young Jonathan sold $25,210 worth of shares (586 units at $43.02), decreasing direct ownership by 0.30% to 196,898 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Development Officer Yale Catriona sold $28,350 worth of shares (659 units at $43.02), decreasing direct ownership by 0.72% to 90,829 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Financial Officer White William Richard sold $28,350 worth of shares (659 units at $43.02), decreasing direct ownership by 1% to 57,752 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Scientific Officer Rolph Timothy sold $23,790 worth of shares (553 units at $43.02), decreasing direct ownership by 0.33% to 166,571 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- President and CEO Cheng Andrew sold $1,374,665 worth of shares (31,796 units at $43.23) and exercised 14,941 shares at a strike of $8.10, decreasing direct ownership by 3% to 473,902 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Scientific Officer Rolph Timothy sold $552,137 worth of shares (12,500 units at $44.17) and exercised 12,500 shares at a strike of $15.18 (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Operating Officer Young Jonathan exercised 12,500 shares at a strike of $21.10 and sold $576,035 worth of shares (12,500 units at $46.08) (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Technology Officer Gangloff Scott A. exercised 2,600 shares at a strike of $19.62, increasing direct ownership by 11% to 26,351 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Operating Officer Young Jonathan exercised 12,500 shares at a strike of $21.10 and sold $597,326 worth of shares (12,500 units at $47.79) (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- President and CEO Cheng Andrew sold $1,457,596 worth of shares (30,000 units at $48.59), decreasing direct ownership by 6% to 490,757 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Director Henderson Jane exercised 3,000 shares at a strike of $7.01 and sold $142,371 worth of shares (3,000 units at $47.46) (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Scientific Officer Rolph Timothy exercised 12,500 shares at a strike of $21.09 and sold $616,299 worth of shares (12,500 units at $49.30) (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Development Officer Yale Catriona exercised 10,000 shares at a strike of $19.87 and sold $529,467 worth of shares (10,000 units at $52.95) (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- President and CEO Cheng Andrew sold $1,534,895 worth of shares (30,000 units at $51.16), decreasing direct ownership by 5% to 520,757 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Scientific Officer Rolph Timothy exercised 12,500 shares at a strike of $21.09 and sold $638,661 worth of shares (12,500 units at $51.09) (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Senior VP, Commercial Strategy Lamy Patrick sold $105,760 worth of shares (2,000 units at $52.88), decreasing direct ownership by 6% to 29,891 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Development Officer Yale Catriona was granted 890 shares, increasing direct ownership by 0.98% to 91,488 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Operating Officer Young Jonathan was granted 890 shares, increasing direct ownership by 0.45% to 197,484 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Senior VP, Commercial Strategy Lamy Patrick was granted 193 shares, increasing direct ownership by 0.61% to 31,891 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Technology Officer Gangloff Scott A. was granted 299 shares, increasing direct ownership by 1% to 23,751 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Scientific Officer Rolph Timothy was granted 890 shares, increasing direct ownership by 0.54% to 167,124 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- President and CEO Cheng Andrew was granted 890 shares, increasing direct ownership by 0.16% to 550,757 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Financial Officer White William Richard was granted 890 shares, increasing direct ownership by 2% to 58,411 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- President and CEO Cheng Andrew sold $363,041 worth of shares (6,620 units at $54.84), decreasing direct ownership by 1% to 549,867 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Technology Officer Gangloff Scott A. sold $46,504 worth of shares (848 units at $54.84), decreasing direct ownership by 3% to 23,452 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Senior VP, Commercial Strategy Lamy Patrick sold $47,766 worth of shares (875 units at $54.59), decreasing direct ownership by 3% to 31,698 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Scientific Officer Rolph Timothy sold $61,914 worth of shares (1,129 units at $54.84), decreasing direct ownership by 0.67% to 166,234 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Financial Officer White William Richard sold $89,609 worth of shares (1,634 units at $54.84), decreasing direct ownership by 3% to 57,521 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Development Officer Yale Catriona sold $89,554 worth of shares (1,633 units at $54.84), decreasing direct ownership by 2% to 90,598 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Operating Officer Young Jonathan sold $79,683 worth of shares (1,453 units at $54.84), decreasing direct ownership by 0.73% to 196,594 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Development Officer Yale Catriona exercised 10,000 shares at a strike of $21.10 and sold $542,306 worth of shares (10,000 units at $54.23) (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Senior VP, Commercial Strategy Lamy Patrick exercised 2,000 shares at a strike of $19.87 and sold $108,272 worth of shares (2,000 units at $54.14) (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- President and CEO Cheng Andrew sold $2,044,940 worth of shares (37,837 units at $54.05), decreasing direct ownership by 6% to 556,487 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Scientific Officer Rolph Timothy sold $127,323 worth of shares (2,358 units at $54.00), decreasing direct ownership by 1% to 167,363 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
- Chief Financial Officer White William Richard sold $151,402 worth of shares (2,804 units at $53.99), decreasing direct ownership by 5% to 59,155 units (SEC Form 4)4 - Akero Therapeutics, Inc. (0001744659) (Issuer)